Cancer survival in patients from a hospital-based cancer registry, China

Abstract

Purpose: There are few reports on survival rate analysis from hospital-based cancer registries (HBCR) in China, although the National Center of Cancer Registry of China has launched such an effort with the mission to expand the scope of registration and follow-up. Our study aimed to evaluate survival and outcomes of cancer patients from a HBCR in eastern China.Methods: Active and passive follow-up methods were used to obtain information on survival status for all patients from Qidong City and Haimen City in the databases of our hospital-based registrations from 2002 to 2014. Censor time for survival was 31st March, 2016. Survival probability was estimated using the life-table method with SPSS Statistics software, and comparison of significant differences in survival rates was tested by Wilcoxon (Gehan) statistic.Results: The outcomes of 5010 patients were identified in the follow-up for 5244 cases from Qidong and Haimen, with a follow-up rate of 95.65%, and a rate of lost to follow-up of 4.35%. The 1-, 3-, 5-, and 10-year observed survival (OS) rate in all-combined cancer sites were 59.80%, 37.70%, 30.82%, and 22.60%, respectively. The top 10 cancer sites in rank were cancers of lung, esophagus, liver, cervix, stomach, breast, colon-rectum, non-Hodgkin's lymphoma, nasopharynx, and ovary, with 5-year OS rates of 12.63%, 19.62%, 11.69%, 66.61%, 21.35%, 59.43%, 36.36%, 37.03%, 48.95% and 36.17%, respectively. Females experienced better survival than males for lung, esophageal, liver, nasopharyngeal and pancreatic cancers (P<0.05), but not for other sites (P>0.05). A significant difference was also found between males and females when all-sites were combined (P<0.01). There are significant differences (P<0.05) between the 2015 patients (from Qidong) and the 3001 patients (from Haimen) with 5-year OS rates of 32.72% vs 29.57%; no significant differences were found for 5-year OS rates for individual cancer sites (P>0.05) except for liver (P=0.0005) and ovary (P=0.0460) between the two cities. Younger patients had better prognosis, but significance was only seen in cervical (P=0.0102) and nasopharyngeal (P=0.0305) cancers.Conclusion: The survival rates of each site or of all sites-combined in this setting are consistent with those elsewhere in China and abroad. Discrepancies in overall survival could be affected by the proportion of sites with or without better prognosis. Hospital-based cancer survival is a better index to evaluate outcomes that reflect the levels of comprehensive treatment and improvement of medical and health services.

Individual- and Area-Level Socioeconomic Inequalities in Esophageal Cancer Survival in Shandong Province, China: A Multilevel Analysis

“…The national study is based on data from 17 cancer registries in east China, with one of the registries located in Shandong Province (30). Two other survival analyses based on data from two county-level cancer registries located in east and west China reported 5-year all-cause survival for esophageal cancer as 19.6% in 2002-2014 and 18.6% in 2008-2013, respectively (31,32). Although the different survival measurements were not directly comparable, results from this study are largely consistent with other Chinese studies at similar period.…”

Survival Rate of Prostate Cancer in Asian Countries: A Systematic Review and Meta-Analysis

“…The included studies were published from 1998 to 2018. Based on geographical locations, nine studies were conducted in Korea [19,20,21,30,31,32,33,34,35], five in China [18,36,[37][38][39], five in Japan [40][41][42][43][44], four in India [45][46][47][48], four in Thailand [49][50][51][52], two in Singapore [53,54], two in Taiwan [55,56], one in Hong Kong [57], one in the Philippines [58], one involved Chinese residents in Singapore [59], one involved countries (China, India and Singapore) [60], one involved the Asian population in England [61]. Characteristics of the included studies are presented in Table 1.…”

MicroRNA‐26a‐5p inhibits breast cancer cell growth by suppressing RNF6 expression

“…Breast cancer is one of the most common malignant tumors in women . According to statistics, the incidence of breast cancer accounts for 7% to 10% of all malignant tumors in the body, and there are about 40 000 people died of breast cancer every year in China, which is next to uterine carcinoma .…”